Regeneron Pharmaceuticals & Bayer Healthcare have announced the submission of a marketing authorisation application (MAA) for VEGF Trap Eye for the treatment of neovascular age related macular degeneration (AMD). The announcement follows less than two months after the companies announced plans to initiate two Phase III trials of VEGF Trap Eye for diabetic macular edema and highlights the significant commercial attraction of anti-VEGF plays in the retinal market.